We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:
Medicine & public health

Search Results

Showing 1-20 of 10,000 results

  1. The potential value of ultrasound in predicting local refractory/relapse events in primary thyroid lymphoma patients

    Background

    Primary thyroid lymphoma (PTL) is a rare malignant disorder, and ultrasound plays an important role in PTL diagnosis and follow-up...

    Jiang Ji, Luying Gao, ... Yuxin Jiang in Cancer Imaging
    Article Open access 20 March 2024

  2. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone

    Background

    The patients with multisystem and risk organ involvement Langerhans cell histiocytosis (MS-RO + LCH) have poor prognosis. The patients with...

    Wenqian Wang, Jian Ge, ... Rui Zhang in BMC Pediatrics
    Article Open access 03 January 2024

  3. CD4 + and CD8 + T-lymphocyte number as predictive marker of relapse after rituximab treatment in childhood-onset refractory nephrotic syndrome

    Background

    Rituximab is a promising option for refractory idiopathic nephrotic syndrome. However, no simple predictive markers for relapse after...

    Toru Kanamori, Koichi Kamei, ... Shuichi Ito in Clinical and Experimental Nephrology
    Article 24 April 2023

  4. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing

    Background

    BCMA CAR-T is highly effective for relapsed/refractory multiple myeloma(R/R-MM) and significantly improves the survival of patients....

    Wei Li, Binglei Zhang, ... Yong** Song in Experimental Hematology & Oncology
    Article Open access 08 May 2023

  6. The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies

    Purpose

    Patients with relapse and/or refractory multiple myeloma (RRMM) have a high disease burden with poor health-related quality of life (HRQoL)...

    Ademola S. Ojo, Mojisola O. Araoye, ... Ravi Sarma in Journal of Cancer Survivorship
    Article 16 January 2023

  7. Identification of prognostic factors and construction of a nomogram for patients with relapse/refractory adult-onset Still’s disease

    Objectives

    This study aimed to identify the risk factors for relapse/refractory adult-onset Still’s disease (AOSD) and to construct and validate a...

    Ruxue Yin, Gangjian Wang, ... Shengyun Liu in Clinical Rheumatology
    Article 18 May 2021

  8. Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified

    Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R)...

    Kaiqi Liu, Yan Li, ... Yingchang Mi in Experimental Hematology & Oncology
    Article Open access 16 September 2021

  9. A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma

    Checkpoint inhibitors have significantly changed the prognosis of patients with relapsing refractory classical Hodgkin’s lymphoma (cHL),...

    Francesco Gaudio, Giacomo Loseto, ... Pellegrino Musto in Annals of Hematology
    Article 16 January 2023

  10. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

    We performed a retrospective multicenter study including 140 patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who...

    Leyre Bento, Antonio Gutiérrez, ... Dolores Caballero in Bone Marrow Transplantation
    Article 25 March 2021

  11. Correction to: Eltrombopag is effective in patients with relapse/refractory aplastic anemia—report from a single center in China

    The article “Eltrombopag is effective in patients with relapse/refractory aplastic anemia—report from a single center in China”.

    **g Ruan, Wei Zuo, ... Bing Han in Annals of Hematology
    Article 02 November 2020

  12. Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study

    Background

    Tacrolimus (TAC) is a powerful remission-inducing drug for refractory ulcerative colitis (UC). However, it is unclear whether mucosal...

    Ayumi Ito, Syun Murasugi, ... Katsutoshi Tokushige in BMC Gastroenterology
    Article Open access 26 June 2020

  13. Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study

    Purpose

    To analyze the effectiveness of decitabine combined with low-dose Ara‑C, aclarubicin, and rhG-CSF (DCAG) as a salvage therapy in patients with...

    Yu Fu, Long Su, ... Yehui Tan in memo - Magazine of European Medical Oncology
    Article 20 November 2023

  14. Regular assessment of serum vascular endothelial growth factor levels to monitor POEMS syndrome

    Background

    To investigate the utility of regular serum VEGF (sVEGF) levels assessment in the monitoring of POEMS syndrome.

    Methods

    We retrospectively...

    Francesco Gentile, Fabrizia Terenghi, ... Eduardo Nobile-Orazio in Neurological Sciences
    Article Open access 13 September 2023

  15. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

    We compared FT14 (fludarabine 150–160 mg/m 2 , treosulfan 42 g/m 2 ) versus FB4 (fludarabine 150–160 mg/m 2 , busulfan 12.8 mg/kg) in acute myeloid...

    Eleni Gavriilaki, Ioanna Sakellari, ... Mohamad Mohty in Bone Marrow Transplantation
    Article 07 July 2023

  16. Novel CAR T cell therapies for patients with large B cell lymphoma

    Approximately 60–70% of patients with large B cell lymphoma (LBCL) achieve long-term remission or a cure after initial treatment. However, patients...

    Hideki Goto, Masahiro Onozawa, Takanori Teshima in International Journal of Hematology
    Article 25 May 2024

  18. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

    Pre-transplant detectable measurable residual disease (MRD) is still associated with high risk of relapse and poor outcomes in acute myeloid leukemia...

    Iman Abou Dalle, Myriam Labopin, ... Mohamad Mohty in Bone Marrow Transplantation
    Article 11 April 2023

  19. Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study

    Standard therapy for patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL) involves salvage chemotherapy followed by autologous...

    Charanpreet Singh, Aditya Jandial, ... Gaurav Prakash in Indian Journal of Hematology and Blood Transfusion
    Article 29 August 2023

  20. Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study

    Blinatumomab is a bispecific T-cell engager approved for relapsed/refractory and minimal residual disease positive B-cell Acute Lymphoblastic...

    Salvatore Leotta, Uros Markovic, ... Giuseppe Milone in Annals of Hematology
    Article 13 April 2024
Did you find what you were looking for? Share feedback.